CTLA4 and melanoma: To test this hypothesis, we coupled spatially resolved tumor molecular profiling with micro-tumor analysis (Fig. 1b) and immune neighbor analysis (Fig. 1c) to analyze thin FFPE tumor sections resected from 13 patients with recurrent GBM (treated with anti-PD1) and 23 patients with high-risk melanoma (treated with anti-PD1 ± anti-CTLA4).